The short answer
Ciudin and colleagues published a Bayesian network meta-analysis in Advances in Therapy in 2026 comparing tirzepatide, semaglutide 2.4 mg and liraglutide 3 mg indirectly. Six of 42 identified randomised trials entered the network after a heterogeneity assessment. The study was sponsored by Eli Lilly.
Key facts
- Publication
- Adv Ther 2026;43(5):2090-2105 (PMID 41820778)
- Method
- Systematic literature review plus Bayesian network meta-analysis
- Trials identified
- 42
- Trials included
- 6
- Included trials
- SURMOUNT-1, STEP 1, STEP 5, STEP 8, O'Neil 2018, SCALE Obesity and Prediabetes
- Population
- Adults without type 2 diabetes, BMI 30+ or 27+ with one complication
- Tirzepatide 15 mg vs semaglutide
- -6.26% weight (efficacy estimand)
- Tirzepatide 15 mg vs liraglutide
- -13.95% weight (efficacy estimand)
- Sponsor
- Eli Lilly
What the analysis set out to do
No trial has randomised all three of tirzepatide, semaglutide and liraglutide against each other, and until recently no trial had randomised tirzepatide against either. A network meta-analysis fills that gap by linking trials through shared comparators: if trial A compares drug 1 with placebo and trial B compares drug 2 with placebo, the two drugs can be compared indirectly through their common placebo arms. This analysis did that for semaglutide 2.4 mg, liraglutide 3 mg and tirzepatide at 5, 10 and 15 mg, in adults without type 2 diabetes with obesity or with overweight plus at least one obesity-related complication.
Six of forty-two, and why that is not automatically a criticism
The systematic review identified 42 randomised controlled trials. Six entered the network: SURMOUNT-1, STEP 1, STEP 5, STEP 8, the O'Neil 2018 dose-ranging trial, and SCALE Obesity and Prediabetes. Excluding 86% of the identified evidence sounds damning and is not, necessarily. An indirect comparison is only valid if the trials being linked are exchangeable: similar populations, similar background therapy, similar outcome definitions. Trials that differ on those dimensions do not add information; they add bias. Discarding them is the correct move. But it is also a decision that determines the answer, made by the analysts, and it is the first thing to interrogate in any network meta-analysis. The paper reports its inclusion reasoning explicitly, which is what allows the interrogation to happen.
Research material referenced
Retatrutide 10mg, third-party HPLC tested
What it found
On the efficacy estimand, all three tirzepatide doses produced statistically greater weight reduction than liraglutide, and tirzepatide 10 mg and 15 mg produced statistically greater reduction than semaglutide. Against liraglutide, percentage weight reduction was -12.86% for tirzepatide 10 mg and -13.95% for 15 mg. Against semaglutide 2.4 mg, the corresponding figures were -4.85% and -6.26%. Waist circumference moved in the same direction: -11.79 cm and -12.30 cm against liraglutide, -4.81 cm and -5.32 cm against semaglutide. Safety profiles were reported as generally comparable across all three. Tirzepatide 5 mg was broadly comparable with semaglutide rather than superior to it, which is a detail that tends to disappear in summaries.
The part that makes this analysis unusually interesting
SURMOUNT-5, the open-label head-to-head trial of tirzepatide against semaglutide, was published after this analysis was conducted. The authors say so, and state their reason for not adding it: the maximum-tolerated-dose design meant the response could not be attributed to a specific dose, so it was not translatable to the fixed-dose structure of their network. That makes the comparison that follows independent. SURMOUNT-5 randomised 751 adults for 72 weeks and reported -20.2% with tirzepatide against -13.7% with semaglutide, a difference of 6.5 percentage points. The network meta-analysis, using no head-to-head data at all, estimated -6.26% for tirzepatide 15 mg against semaglutide 2.4 mg. The indirect estimate and the direct trial agree to within a quarter of a percentage point.
Why that agreement matters, and how far to push it
Indirect comparison is routinely dismissed as a weaker substitute for a real trial, and in the hierarchy of evidence it is. But this is a documented case in which an indirect estimate predicted a subsequent head-to-head result almost exactly, in a field where nobody had run the head-to-head yet. That is worth knowing when a health technology assessment rests on indirect evidence, which many do. The caveats are real and should travel with the claim: SURMOUNT-5 used a mix of 10 mg and 15 mg tirzepatide against a mix of 1.7 mg and 2.4 mg semaglutide, so it is not a clean 15 mg versus 2.4 mg comparison; it was open-label where the network's trials were mostly double-blind; and one agreement does not establish that indirect comparison is generally reliable. It establishes that it was reliable here.
Who paid for it, and why that is stated rather than implied
The study was sponsored by Eli Lilly, which markets tirzepatide, and Lilly also funded the journal's rapid service and open access fees. Five of the nine authors are declared employees and shareholders of Eli Lilly. Three are employees of Costello Medical, which was paid by Lilly for analytical services for this study. The remaining author declares honoraria from AstraZeneca, Boehringer Ingelheim, Lilly and Novo Nordisk. All of that is stated in the paper's own declarations, in full. The correct response is not to discard the analysis (a sponsored study is not a false one, and the SURMOUNT-5 agreement is evidence that this one estimated well) but to hold the funding in mind against the choices only the analysts could make, of which the exclusion of 36 trials is the largest.
Quick reference
| Trial in the network | Year | Drug studied | Sample size in Table 1 |
|---|---|---|---|
| SCALE Obesity and Prediabetes | 2015 | Liraglutide 3 mg | 4,974 |
| O'Neil dose-ranging | 2018 | Semaglutide vs liraglutide | 239 |
| STEP 1 | 2021 | Semaglutide 2.4 mg | 1,961 |
| STEP 5 | 2022 | Semaglutide 2.4 mg | 304 |
| STEP 8 | 2022 | Semaglutide vs liraglutide | 338 |
| SURMOUNT-1 | 2022 | Tirzepatide 5/10/15 mg | 2,539 |
Frequently asked questions
Does this replace a head-to-head trial?
No, and the paper does not claim it does. An indirect estimate carries assumptions that a randomised comparison does not need. Its value is that it exists where a head-to-head does not. For tirzepatide against liraglutide, that remains the case.
Should a sponsored meta-analysis be trusted?
It should be read with its sponsorship known, which the disclosure makes possible. Sponsorship is associated on average with results favourable to the sponsor, and that association is a reason for scrutiny rather than a verdict on any single paper. Here the scrutiny is available: the inclusion criteria are stated, the six trials are named, and the central estimate was subsequently matched by an independent trial.
Why exclude 36 trials?
Because a network meta-analysis is only valid if the linked trials are comparable enough that their placebo arms can stand in for each other. Trials in different populations, with different background therapy or different outcome definitions, break that assumption. The exclusions are defensible in principle; whether each one was correct requires reading the supplementary material.
Is tirzepatide therefore better than semaglutide?
On weight reduction at the doses studied, both this analysis and SURMOUNT-5 point the same way, and that is now reasonably well supported. Both are licensed medicines that we do not supply, nothing sold on this site is an alternative to either, and 'better on average weight change' is not the same as 'better for a given person', which depends on tolerability, comorbidity and access.
Continue researching
Related guides and reference material.
Primary sources & clinical trials
Published papers, trial registrations, regulator pages and company announcements. Links open the original.
- PubMedCiudin A et al., Comparison of Clinical Efficacy and Safety of Tirzepatide, Liraglutide and Semaglutide in Patients with Obesity and Without T2D: A Bayesian Network Meta-Analysis - Adv Ther 2026 (PMID 41820778)pubmed.ncbi.nlm.nih.gov
- PubMedAronne LJ et al., Tirzepatide as Compared with Semaglutide for the Treatment of Obesity - NEJM 2025 (PMID 40353578)pubmed.ncbi.nlm.nih.gov
- PubMedJastreboff AM et al., Tirzepatide Once Weekly for the Treatment of Obesity - NEJM 2022 (PMID 35658024)pubmed.ncbi.nlm.nih.gov
- PubMedWilding JPH et al., Once-Weekly Semaglutide in Adults with Overweight or Obesity - NEJM 2021 (PMID 33567185)pubmed.ncbi.nlm.nih.gov
- PubMedGarvey WT et al., Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial - Nat Med 2022 (PMID 36216945)pubmed.ncbi.nlm.nih.gov
- PubMedRubino DM et al., Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight - JAMA 2022 (PMID 35015037)pubmed.ncbi.nlm.nih.gov
- PubMedO'Neil PM et al., Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss - Lancet 2018 (PMID 30122305)pubmed.ncbi.nlm.nih.gov
- PubMedPi-Sunyer X et al., A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management - NEJM 2015 (PMID 26132939)pubmed.ncbi.nlm.nih.gov
Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).
Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.
More GLP-1 & Incretin Science articles
- Tirzepatide Has No Active Comparator in the NetworkIn the 2026 obesity network meta-analysis, tirzepatide links to every other drug only through placebo arms. That structure is where the assumptions live.
- Three Studies, Three Numbers, No ContradictionPublished FAERS analyses give semaglutide kidney-injury figures of 0.44, 1.25 and 3.15. All three are correct, because each uses a different comparator.
- Why a Safety Report Count ClimbsTirzepatide ketoacidosis reports rose from 1-2 per quarter in 2022 to 28-34 by 2025. Almost all of that curve is uptake and reporting behaviour, not risk.
- The Complication That Hides Behind a Normal GlucoseKetoacidosis with near-normal glucose is easy to miss: the test that usually raises the alarm looks reassuring. Both incretin drugs show reporting signals.
- Disclosure Is Not DisqualificationA 2026 obesity meta-analysis declares its sponsor, its employee authors and its paid contractors in full. That transparency is what makes scrutiny possible.